Several previous meta-analyses have compared the efficacies of ALK inhibitors in patients with ALK-p, ALK inhibitor-naive advanced NSCLC [39,40,97,98,99,100,101,102,103,104]. This evidence concerns the gene ALK and non-small cell lung carcinoma.